Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference in NYC on February 16
Untitled Document

HOPKINTON, MA / ACCESSWIRE / February 7, 2017 / Spring Bank Pharmaceuticals Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals, will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 2:15 PM Eastern Time in Track 1 - Tribeca at the Convene Conference Center in New York City.

Management will be available to meet with investors throughout the day. Investors wishing to schedule a meeting should contact Spring Bank at jfreve@springbankpharm.com.

The 2017 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

A live and archived webcast of the event will be available online through Spring Bank's investor relations site at www.springbankpharm.com.

News Compliments of Accesswire.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body's immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body's immune response through its mechanisms of action to fight viral infections such as HBV. For more information, please visit: www.springbankpharm.com.

For those interested in attending, please visit www.DisruptNYC.com for more information.

Contact:

Jon Freve
Chief Financial Officer
(508) 500-4956
jfreve@springbankpharm.com

SOURCE: Spring Bank Pharmaceuticals